All 1 tracked stories fall under one category: pharma. Centers for Medicare & Medicaid Services is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention DMEPOS, all published on March 6, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about DMEPOS
All 1 tracked stories fall under one category: pharma. Centers for Medicare & Medicaid Services is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention DMEPOS, all published on March 6, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering DMEPOS. Shared-story counts are live from our verified record — not editorial picks.
The Centers for Medicare & Medicaid Services (CMS) has implemented a six-month nationwide freeze on new Medicare enrollments for seven categories of medical supply companies. This aggressive regulatory move, effective February 27, 2026, aims to curb systemic fraud and billions in improper payments within the DMEPOS sector.
DMEPOS is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.